Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma have?
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma has 679 citations in the OpenAlex counts ScholarIQ stores.
When was Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma published?
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma has 2019 year in the ScholarIQ index.
What is the open-access status of Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma?
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma has bronze oa status in the ScholarIQ index.
What is the DOI of Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma?
The DOI for Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma is on the source record.
What is the PMID of Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma?
The PMID for Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma is on the source record.
What is the OpenAlex record for Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma?
The OpenAlex for Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma is on the source record.